Monographie - Dactinomycin

Última actualización :
19/11/2024

Dactinomycin

Factores que influyen sobre la estabilidad

Estructura química

Nombre comercial

Los nombres comerciales son orientativos y los excipientes de la formulación pueden ser distintos dependiendo del país y del laboratorio fabricante.

Cosmegen	Argentina, Australia, Austria, Canadá, Estados Unidos de América, Finlandia, Francia, Grecia, Irán, Italia, Malasia, México, Noruega, Nueva Zelanda, Suecia, Suiza
Cosmegen Lyovac	Gran Bretaña, Irlanda, Rumania
Dacilon	Chile, India, Marruecos
Dacmozen	India
Dactino	India
Dactinomicina	Chile, Colombia, Ecuador, Marruecos
Dactinomycin	Nueva Zelanda
Lyovac Cosmegen	Alemania, Bélgica, Luxemburgo, Países Bajos

Bibliografía : Dactinomycin

	Tipo	Publicación
3	periódico	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
84	periódico	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	periódico	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	periódico	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	periódico	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	periódico	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	periódico	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	periódico	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	periódico	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	periódico	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	periódico	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
729	periódico	Rusmin S, Welton S, DeLuca P, DeLuca PP. Effect of inline filtration on the potency of drugs administered intravenously. Am J Hosp Pharm 1977 ; 34: 1071-1074.
857	periódico	Kanke M, Eubanks JL, DeLuca PP. Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 ; 40: 1323-1328.
905	periódico	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1178	periódico	Benvenuto JA, Anderson RW, Kerkof K, Smith RG, Loo TL. Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 ; 38: 1914-1918.
1322	periódico	Ennis CE, Merritt RJ, Neff DN. In vitro study of inline filtration of medications commonly administered to pediatric cancer patients. JPEN 1983 ; 7: 156-158.
1410	periódico	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	periódico	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
4153	Laboratorio	Dactinomycin (Cosmegen Lyovac®) - Summary of Product Characteristics Orphan Europe (UF) Limited 2014

Mentions Légales